A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After New Oncology Regulatory Milestones

Simply Wall St.
May 20

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after fresh oncology pipeline news, including priority review for sacituzumab tirumotecan in lung cancer and clinical trial ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10